Vol 53, No 3 (2019)
Review article
Published online: 2019-06-05
Submitted: 2019-03-13
Accepted: 2019-05-16
Get Citation

Prevention of epilepsy in humans – truth or myth? The experience from Sturge-Weber syndrome and Tuberous Sclerosis Complex

Monika Słowińska, Weronika Golec, Sergiusz Jóźwiak
DOI: 10.5603/PJNNS.a2019.0022
·
Pubmed: 31166003
·
Neurol Neurochir Pol 2019;53(3):190-193.

paid access

Vol 53, No 3 (2019)
Review article
Published online: 2019-06-05
Submitted: 2019-03-13
Accepted: 2019-05-16

Abstract

Introduction. Epilepsy is a chronic neurological disease, usually decreasing the quality of life and often resulting in other comorbidities e.g. cognitive impairment in children. Despite the recent discovery of new antiepileptic drugs, roughly one in three patients suffers from drug-resistant seizures. Therefore, the prevention of epilepsy is becoming one of the most important challenges in medicine. Is it, however, in fact possible to prevent epilepsy?

Clinical reflections and implications. We present the results of preventive antiepileptic treatment in children with Sturge-Weber syndrome and Tuberous Sclerosis Complex as examples of the possible prevention of epilepsy and epilepsy-associated cognitive impairment in children.

Abstract

Introduction. Epilepsy is a chronic neurological disease, usually decreasing the quality of life and often resulting in other comorbidities e.g. cognitive impairment in children. Despite the recent discovery of new antiepileptic drugs, roughly one in three patients suffers from drug-resistant seizures. Therefore, the prevention of epilepsy is becoming one of the most important challenges in medicine. Is it, however, in fact possible to prevent epilepsy?

Clinical reflections and implications. We present the results of preventive antiepileptic treatment in children with Sturge-Weber syndrome and Tuberous Sclerosis Complex as examples of the possible prevention of epilepsy and epilepsy-associated cognitive impairment in children.

Get Citation

Keywords

epilepsy, prevention, tuberous sclerosis, Sturge-Weber

About this article
Title

Prevention of epilepsy in humans – truth or myth? The experience from Sturge-Weber syndrome and Tuberous Sclerosis Complex

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 53, No 3 (2019)

Pages

190-193

Published online

2019-06-05

DOI

10.5603/PJNNS.a2019.0022

Pubmed

31166003

Bibliographic record

Neurol Neurochir Pol 2019;53(3):190-193.

Keywords

epilepsy
prevention
tuberous sclerosis
Sturge-Weber

Authors

Monika Słowińska
Weronika Golec
Sergiusz Jóźwiak

References (31)
  1. Behr C, Goltzene MA, Kosmalski G, et al. Epidemiology of epilepsy. Rev Neurol (Paris). 2016; 172(1): 27–36.
  2. Garcia-Ramos C, Dabbs K, Meyerand E, et al. Psychomotor slowing is associated with anomalies in baseline and prospective large scale neural networks in youth with epilepsy. Neuroimage Clin. 2018; 19: 222–231.
  3. Lenck-Santini PP, Scott RC. Mechanisms Responsible for Cognitive Impairment in Epilepsy. Cold Spring Harb Perspect Med. 2015; 5(10).
  4. Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018; 59(12): 2179–2193.
  5. Pitkänen A, Lukasiuk K, Dudek FE, et al. Epileptogenesis. Cold Spring Harb Perspect Med. 2015; 5(10).
  6. Clossen BL, Reddy DS. Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(6): 1519–1538.
  7. Graham N, Crichton S, Koutroumanidis M, et al. Incidence and Associations of Poststroke Epilepsy. Stroke. 2013; 44(3): 605–611.
  8. Englander J, Bushnik T, Duong TT, et al. Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. Arch Phys Med Rehabil. 2003; 84(3): 365–373.
  9. Comi AM. Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies. Lymphat Res Biol. 2007; 5(4): 257–264.
  10. Comi AM. Sturge-Weber syndrome. Handb Clin Neurol. 2015; 132: 157–168.
  11. Sudarsanam A, Ardern-Holmes SL. Sturge-Weber syndrome: from the past to the present. Eur J Paediatr Neurol. 2014; 18(3): 257–266.
  12. Ville D, Enjolras O, Chiron C, et al. Prophylactic antiepileptic treatment in Sturge-Weber disease. Seizure. 2002; 11(3): 145–150.
  13. Kaseka ML, Bitton JY, Décarie JC, et al. Predictive Factors for Epilepsy in Pediatric Patients With Sturge-Weber Syndrome. Pediatr Neurol. 2016; 64: 52–58.
  14. Pinto A, Sahin M, Pearl PL. Epileptogenesis in neurocutaneous disorders with focus in Sturge Weber syndrome. F1000Res. 2016; 5.
  15. Alkonyi B, Chugani HT, Juhász C. Transient focal cortical increase of interictal glucose metabolism in Sturge-Weber syndrome: implications for epileptogenesis. Epilepsia. 2011; 52(7): 1265–1272.
  16. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008; 372(9639): 657–668.
  17. Słowińska M, Jóźwiak S, Peron A, et al. Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures? Orphanet J Rare Dis. 2018; 13(1): 25.
  18. Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010; 51(7): 1236–1241.
  19. Domańska-Pakieła D, Kaczorowska M, Jurkiewicz E, et al. EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients - a prospective study of 5 patients. Eur J Paediatr Neurol. 2014; 18(4): 458–468.
  20. Whitney R, Jan S, Zak M, et al. The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex. Pediatr Neurol. 2017; 72: 76–80.
  21. Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011; 15(5): 424–431.
  22. Caban C, Khan N, Hasbani DM, et al. Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet. 2017; 10: 1–8.
  23. Sadowski K, Kotulska-Jóźwiak K, Jóźwiak S. Role of mTOR inhibitors in epilepsy treatment. Pharmacol Rep. 2015; 67(3): 636–646.
  24. Salussolia CL, Klonowska K, Kwiatkowski DJ, et al. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex. Annu Rev Genomics Hum Genet. 2019 [Epub ahead of print].
  25. Schubert-Bast S, Rosenow F, Klein KM, et al. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives. Epilepsy Behav. 2019; 91: 94–98.
  26. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013; 381(9861): 125–132.
  27. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381(9869): 817–824.
  28. McCormack FX, Inoue Y, Moss J, et al. National Institutes of Health Rare Lung Diseases Consortium, MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364(17): 1595–1606.
  29. Jóźwiak S, Sadowski K, Kotulska K, et al. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature. Pediatr Neurol. 2016; 61: 21–27.
  30. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016; 388(10056): 2153–2163.
  31. Jóźwiak S, Kotulska K. Prevention of epileptogenesis--a new goal for epilepsy therapy. Pediatr Neurol. 2014; 51(6): 758–759.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl